ACHV
What one share of Achieve Life Sciences holds
In Vitro and In Vivo Diagnostic Substances
We are a late-stage clinical specialty pharmaceutical company with the sole mission to address the global nicotine dependence epidemic through the development and commercialization of cytisinicline. There are an estimated 29 million adults in the United States alone who smoke combustible cigarettes and an estimated 17 million adults in the United States who utilize e-cigarettes.
Achieve Life Sciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.81 |
|---|---|
| Cash and investments | $1.82 |
| Book value | −$0.14 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$441.47 | — | −$379.90 | — | — |
| 2018 | $0.00 | −$72.29 | $0.26 | −$60.79 | — | $47.02 |
| 2019 | $0.00 | −$39.76 | $0.13 | −$37.03 | — | — |
| 2020 | — | −$5.42 | $0.01 | −$4.96 | — | — |
| 2021 | — | −$4.08 | — | −$3.63 | — | $2.97 |
| 2022 | — | −$4.00 | — | −$3.55 | — | $0.46 |
| 2023 | — | −$1.50 | $0.00 | −$1.24 | — | −$0.07 |
| 2024 | — | −$1.24 | — | −$0.93 | — | $0.60 |
| 2025 | — | −$1.25 | $0.00 | −$1.13 | — | $0.40 |